---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005355"
form_type: "8-K"
ticker: "BYSI"
cik: "0001677940"
company_name: "BeyondSpring Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:16.454904+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q2 net loss narrows to $1.9M; Plinabulin shows 23% ORR in ICI-refractory cancers

## Summary
- Net loss from continuing operations $1.9M for Q2 2025 vs $2.7M in Q2 2024; cash $9.5M as of Jun 30, 2025 vs $2.9M Dec 2024.
- R&D expenses $1.0M; G&A $0.9M, down from $1.8M on lower headcount and professional costs.
- Plinabulin combo in PD-1/L1 progressed NSCLC showed median PFS 6.8 mo, ORR 18.2%, DCR 77%, OS 78% at 15 mo.
- SEED Therapeutics' RBM39 degrader ST-01156 cleared FDA IND; Dr. Bill Desmarais appointed CFO and CBO.
- Discontinued operations loss $2.8M vs $1.4M YoY, reflecting SEED reporting change.

## SEC filing metadata
- accession: 0001171843-25-005355
- form_type: 8-K
- ticker: BYSI
- cik: 0001677940
- company_name: BeyondSpring Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677940/000117184325005355/0001171843-25-005355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677940/000117184325005355/f8k_081325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005355
- JSON: https://secwatch.observer/filing/0001171843-25-005355.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.